Have a personal or library account? Click to login
Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts through regulation of the HOXA6/ZBTB12 axis Cover

Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts through regulation of the HOXA6/ZBTB12 axis

Open Access
|Sep 2023

References

  1. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660
  2. Y. Zeng and R. U. Jin, Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer, Semin. Cancer Biol. 86(3) (2022) 566–582; https://doi.org/10.1016/j.semcancer.2021.12.004
  3. E. C. Smyth, M. Nilsson, H. I. Grabsch, N. C. van Grieken and F. Lordick, Gastric cancer, Lancet 396 (2020) 635–648; https://doi.org/10.1016/s0140-6736(20)31288-5
  4. S. S. Joshi and B. D. Badgwell, Current treatment and recent progress in gastric cancer, CA Cancer J. Clin. 71(3) (2021) 264–279; https://doi.org/10.3322/caac.21657
  5. Y. Xiao and D. Yu, Tumor microenvironment as a therapeutic target in cancer, Pharmacol. Ther. 221 (2021) Article ID 107753 (30 pages); https://doi.org/10.1016/j.pharmthera.2020.107753
  6. T. A. Karakasheva, E. W. Lin, Q. Tang, E. Qiao, T. J. Waldron, M. Soni, A. J. Klein-Szanto, V. Sahu, D. Basu, S. Ohashi, K. Baba, Z. T. Giaccone, S. R. Walker, D. A. Frank, E. P. Wileyto, Q. Long, M. C. Dunagin, A. Raj, J. A. Diehl, K. K. Wong, A. J. Bass and A. K. Rustgi, IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment, Cancer Res. 78(17) (2018) 4957–4970; https://doi.org/10.1158/0008-5472.can-17-2268
  7. H. Sun, X. Wang, X. Wang, M. Xu and W. Sheng, The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer, Cell Death Dis. 13 (2022) Article ID 874 (9 pages); https://doi.org/10.1038/s41419-022-05320-8
  8. H. Zhang, T. Deng, R. Liu, T. Ning, H. Yang, D. Liu, Q. Zhang, D. Lin, S. Ge, M. Bai, X. Wang, L. Zhang, H. Li, Y. Yang, Z. Ji, H. Wang, G. Ying and Y. Ba, CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer, Mol. Cancer 19 (2020) Article ID 43 (17 pages); https://doi.org/10.1186/s12943-020-01168-8
  9. X. Liu, L. Yao, J. Qu, L. Liu, N. Lu, J. Wang and J. Zhang, Cancer-associated fibroblast infiltration in gastric cancer: the discrepancy in subtypes pathways and immunosuppression, J. Transl. Med. 19 (2021) Article ID 325 (16 pages); https://doi.org/10.1186/s12967-021-03012-z
  10. G. Itoh, K. Takagane, Y. Fukushi, S. Kuriyama, M. Umakoshi, A. Goto, K. Yanagihara, M. Yashiro and M. Tanaka, Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T-cell suppression, Mol. Oncol. 16(1) (2022) 166–187; https://doi.org/10.1002/1878-0261.13077
  11. Y. Yan, L. F. Wang and R. F. Wang, Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer, World J. Gastroenterol. 21(33) (2015) 9717–9726; https://doi.org/10.3748/wjg.v21.i33.9717
  12. J. Zheng, M. Wu, H. Wang, S. Li, X. Wang, Y. Li, D. Wang and S. Li, Network pharmacology to unveil the biological basis of health-strengthening herbal medicine in cancer treatment, Cancers (Basel) 10(46) (2018) Article ID 461 (23 pages); https://doi.org/10.3390/cancers10110461
  13. J. Liu, S. Wang, Y. Zhang, H. T. Fan and H. S. Lin, Traditional Chinese medicine and cancer: History, present situation, and development, Thorac. Cancer 6(5) (2015) 561–569; https://doi.org/10.1111/1759-7714.12270
  14. J. Zhang, J. Gao, J. Cui, Y. Wang, Y. Jin, D. Zhang, D. Lin and J. Lin, Tumor-associated macrophages in tumor progression and the role of traditional Chinese medicine in regulating TAMs to enhance antitumor effects, Front. Immunol. 13 (2022) Article ID 1026898 (10 pages); https://doi.org/10.3389/fimmu.2022.1026898
  15. Y. Luo, S. Yin, J. Lu, S. Zhou, Y. Shao, X. Bao, T. Wang, Y. Qiu and H. Yu, Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment, Cancer Cell Int. 21 (2021) Article ID 386 (20 pages); https://doi.org/10.1186/s12935-021-02085-6
  16. Y. Zhang, Y. Lou, J. Wang, C. Yu and W. Shen, Research status and molecular mechanism of the traditional Chinese medicine and antitumor therapy combined strategy based on tumor microenvironment, Front. Immunol. 11 (2020) Article ID 609705 (13 pages); https://doi.org/10.3389/fimmu.2020.609705
  17. F. Xu, W. Q. Cui, Y. Wei, J. Cui, J. Qiu, L. L. Hu, W. Y. Gong, J. C. Dong and B. J. Liu, Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling, J. Exp. Clin. Cancer Res. 37 (2018) Article ID 207 (16 pages); https://doi.org/10.1186/s13046-018-0878-0
  18. T. Chen, P. Yang and Y. Jia, Molecular mechanisms of astragaloside-IV in cancer therapy, Int. J. Mol. Med. 47 (2021) Article ID 13 (13 pages); https://doi.org/10.3892/ijmm.2021.4846
  19. Z. Jiang and Z. Mao, Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway, RSC Adv. 9(61) (2019) 35473–35482; https://doi.org/10.1039/c9ra05933d
  20. D. Xia, W. Li, C. Tang and J. Jiang, Astragaloside IV, as a potential anticancer agent, Front. Pharmacol. 14 (2023) Article ID 1065505 (15 pages); https://doi.org/10.3389/fphar.2023.1065505
  21. T. Cai, C. Zhang, Z. Zhao, S. Li, H. Cai, X. Chen, D. Cai, W. Liu, Y. Yan, K. Xie, H. Pan and X. Zeng, The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats, Biomed. Pharma cother. 104 (2018) 291–299; https://doi.org/10.1016/j.biopha.2018.04.013
  22. F. Li, K. Cao, M. Wang, Y. Liu and Y. Zhang, Astragaloside IV exhibits anti-tumor function in gastric cancer via targeting circRNA dihydrolipoamide S-succinyltransferase (circDLST)/miR-489-3p/euka ryotic translation initiation factor 4A1(EIF4A1) pathway, Bioengineered 13(4) (2022) 10111–10122; https://doi.org/10.1080/21655979.2022.2063664
  23. Z. F. Wang, D. G. Ma, Z. Zhu, Y. P. Mu, Y. Y. Yang, L. Feng, H. Yang, J. Q. Liang, Y. Y. Liu, L. Liu and H. W. Lu, Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts, World J. Gastroenterol. 23(48) (2017) 8512–8525; https://doi.org/10.3748/wjg.v23.i48.8512
  24. J. Lin, H. Zhu, L. Hong, W. Tang, J. Wang, H. Hu, X. Wu, Y. Chen, G. Liu, Q. Yang, J. Li, Y. Wang, Z. Lin, Y. Xiao, W. Dai, M. Huang, G. Li, A. Li, J. Wang, L. Xiang and S. Liu, Coexpression of HOXA6 and PBX2 promotes metastasis in gastric cancer, Aging (Albany NY) 13(5) (2021) 6606–6624; https://doi.org/10.18632/aging.202426
  25. G. Biffi and D. A. Tuveson, Diversity and biology of cancer-associated fibroblasts, Physiol. Rev. 101(1) (2021) 147–176; https://doi.org/10.1152/physrev.00048.2019
  26. X. Chen and E. Song, Turning foes to friends: targeting cancer-associated fibroblasts, Nat. Rev. Drug Discov. 18 (2019) 99–115; https://doi.org/10.1038/s41573-018-0004-1
  27. Y. Miyai, N. Esaki, M. Takahashi and A. Enomoto, Cancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives, Cancer Sci. 111(4) (2020) 1047–1057; https://doi.org/10.1111/cas.14346
  28. B. C. Özdemir, T. Pentcheva-Hoang, J. L. Carstens, X. Zheng, C. C. Wu, T. R. Simpson, H. Laklai, H. Sugimoto, C. Kahlert, S. V. Novitskiy, A. De Jesus-Acosta, P. Sharma, P. Heidari, U. Mahmood, L. Chin, H. L. Moses, V. M. Weaver, A. Maitra, J. P. Allison, V. S. LeBleu and R. Kalluri, Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival, Cancer Cell. 25(6) (2014) 719–734; https://doi.org/10.1016/j.ccr.2014.04.005
  29. H. Kobayashi, A. Enomoto, S. L. Woods, A. D. Burt, M. Takahashi and D. L. Worthley, Cancer-associated fibroblasts in gastrointestinal cancer, Nat. Rev. Gastroenterol. Hepatol. 16 (2019) 282–295; https://doi.org/10.1038/s41575-019-0115-0
  30. Y. Lu, Z. Jin, J. Hou, X. Wu, Z. Yu, L. Yao, T. Pan, X. Chang, B. Yu, J. Li, C. Li, M. Yan, C. Yan, Z. Zhu, B. Liu and L. Su, Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer, Matrix Biol. 115 (2023) 1–15; https://doi.org/10.1016/j.matbio.2022.11.005
  31. C. Zhang, L. Li, S. Hou, Z. Shi, W. Xu, Q. Wang, Y. He, Y. Gong, Z. Fang and Y. Yang, Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways, J. Ethnopharmacol. 279(28) (2021) Article ID 114350 (13 pages); https://doi.org/10.1016/j.jep.2021.114350
  32. S. Wang, J. Mou, L. Cui, X. Wang and Z. Zhang, Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3, Biomed. Pharmacother. 102 (2018) 1037–1044; https://doi.org/10.1016/j.biopha.2018.03.127
  33. K. Jiang, Q. Lu, Q. Li, Y. Ji, W. Chen and X. Xue, Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling, Int. Immunopharmacol. 42 (2017) 195–202; https://doi.org/10.1016/j.intimp.2016.10.001
  34. J. Zhu and K. Wen, Astragaloside IV inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cells, Phytother. Res. 32(7) (2018) 1289–1296; https://doi.org/10.1002/ptr.6057
  35. J. Xiulin, C. Wang, J. Guo, C. Wang, C. Pan and Z. Nie, Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma, Aging (Albany NY) 14(6) (2022) 2819–2854; https://doi.org/10.18632/aging.203977
  36. F. Wu, S. Wu, H. Tong, W. He and X. Gou, HOXA6 inhibits cell proliferation and induces apoptosis by suppressing the PI3K/Akt signaling pathway in clear cell renal cell carcinoma, Int. J. Oncol. 54(6) (2019) 2095–2105; https://doi.org/10.3892/ijo.2019.4789
  37. S. Wu, F. Wu and Z. Jiang, Effect of HOXA6 on the proliferation, apoptosis, migration and invasion of colorectal cancer cells, Int. J. Oncol. 52(6) (2018) 2093–2100; https://doi.org/10.3892/ijo.2018.4352
  38. D. Han, G. Liu, Y. Oh, S. Oh, S. Yang, L. Mandjikian, N. Rani, M. C. Almeida, K. S. Kosik and J. Jang, ZBTB12 is a molecular barrier to dedifferentiation in human pluripotent stem cells, Nat. Commun. 14 (2023) Article ID 632 (16 pages); https://doi.org/10.1038/s41467-023-36178-9
  39. Q. Pan, Y. Ning, L. Z. Chen, S. Zhang, Z. Z. Liu, X. X. Yang, W. Wei, H. Wei, Q. G. Li, H. N. Yue and J. X. Wang, Association of MHC class-III gene polymorphisms with ER-positive breast cancer in Chinese Han population, Genet. Mol. Res. 11(4) (2012) 4299–4306; https://doi.org/10.4238/2012.September.17.1
  40. S. Bhatlekar, J. Z. Fields and B. M. Boman, HOX genes and their role in the development of human cancers, J. Mol. Med. 92 (2014) 811–823; https://doi.org/10.1007/s00109-014-1181-y
DOI: https://doi.org/10.2478/acph-2023-0033 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 423 - 439
Accepted on: Jul 30, 2023
|
Published on: Sep 14, 2023
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2023 Haibo Liu, Shicheng Luo, Xiaofeng Sha, Zhiping Chen, Dongdong Yang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.